CN103816476A - Medicine composition for treating injury and paralysis of oculomotor nerve and preparation method and application thereof - Google Patents
Medicine composition for treating injury and paralysis of oculomotor nerve and preparation method and application thereof Download PDFInfo
- Publication number
- CN103816476A CN103816476A CN201310632018.9A CN201310632018A CN103816476A CN 103816476 A CN103816476 A CN 103816476A CN 201310632018 A CN201310632018 A CN 201310632018A CN 103816476 A CN103816476 A CN 103816476A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- raw material
- moschus
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a medicine composition for treating the injury and the paralysis of oculomotor nerves and a preparation method and application thereof. The medicine composition is respectively prepared from the following raw materials in parts by weight: 2 to 8 parts of saffron, 0.1 to 1.0 part of musk, 1 to 5 parts of stir-baked squama manitis, 0.1 to 0.5 part of borneol, 2 to 10 parts of pseudo-ginseng, 1 to 5 parts of nux vomica, 1 to 5 parts of centipede, 24 to 36 parts of astragalus membranaceus, 6 to 15 parts of Chinses angelica, 6 to 15 parts of ligusticum wallichii, 6 to 15 parts of lumbricus, 6 to 15 parts of root of herbaceous peony, 6 to 15 parts of peach kernels, 6 to 15 parts of centipede, 6 to 15 parts of zaocys dhumnade, 6 to 15 parts of centipede, 6 to 15 parts of salvia miltiorrhiza, 6 to 15 parts of rhizoma spargani, 6 to 15 parts of curcuma zedoaria, 6 to 15 parts of safflower, 6 to 15 parts of herba lycopi, and 6 to 15 parts of sapanwood. The medicine composition has obvious effects in clinical use.
Description
Technical field
The present invention relates to technical field of Chinese medicines, be specifically related to pharmaceutical composition of the treatment injury of oculomotor nerve paralysis being prepared from take Chinese herbal medicine as preparation of raw material and its preparation method and application.
Background technology
Oculomotor paralysis is frequently-occurring disease, the commonly encountered diseases of department of acupuncture and moxibustion and Neurology Department.Main manifestations is the ptosis clinically, and eyeball is oblique outward, in upper outside, upper, lower in, there is exotropia and diplopia, platycoria with the side direction dyskinesia; Light reflex and adjusting loss for reaction, head slants tiltedly to strong, regulates and convergence reflex disappearance.Can be divided into completeness and imperfection according to clinical manifestation.The cardinal symptom of injury of oculomotor nerve paralysis: injury of oculomotor nerve, can cause apertor oculi, superior rectus, inferior retcus, medial rectus and inferior obliquus paralysis; Occur that the ptosis, the oblique outer lower side of pupil and pupillary light reflex disappear, the symptoms such as platycoria.After most wounds, find that there is a side platycoria (4-6mm not etc.), photoreaction weakens or disappears, blepharoptosis, and eyeball is inside, upper and lower turns limited, depending on thing ghost image.
Oculomotor paralysis disease is the common disease of cranial nerve infringement, its pathogenic factor is many by due to ocular injury, cerebral trauma, diabetes, basis cranii infection, cerebral infarction, cerebral tumor equivalent damage or compressing oculomotorius, sickness rate increases increasingly, pathogenic factor is more complicated also, site of pathological change is special, belong to and damage capacitive disease, had a strong impact on patient's physical and mental health.Medical circle is being sought this sick effective clinical Therapeutic Method for the treatment of always both at home and abroad, in recent years, the Drug therapy oculomotor paralysis diseases such as acupuncture, hyperbaric oxygen chamber, hormone are obtained good clinical efficacy, demonstrate the unique advantage of the medicines such as acupuncture, hyperbaric oxygen chamber, hormone treatment oculomotor paralysis disease.But, about acupuncture, hyperbaric oxygen chamber, the mechanism of action of the Drug therapy oculomotor paralysis diseases such as hormone it be unclear that, although more existing achievements in research and hypothesis, but still be not enough to explain acupuncture, hyperbaric oxygen chamber, the mechanism of these diseases of Drug therapy such as hormone, need further widen thoughts, from modern medicine and other cross disciplines, find meeting point and clearly treat the mechanism of this disease, to improve better the repairing effect of damage oculomotorius, particularly Chinese traditional traditional Chinese medical science extensive knowledge and profound scholarship, strengthening research, aspect use Traditional Chinese Medicine treatment injury of oculomotor nerve paralysis, be well worth doing.At present, be applied in the research report for the treatment of injury of oculomotor nerve paralysis at Chinese medicine few.
Summary of the invention
The technical problem to be solved in the present invention is for treating the deficiencies such as the undesirable or curative effect of injury of oculomotor nerve paralysis effect is unstable in prior art, pharmaceutical composition of a kind of effective treatment injury of oculomotor nerve paralysis and its preparation method and application being provided.
In pharmaceutical composition of the present invention, the consumption of each component is that inventor draws through a large amount of practice summaries, and this pharmaceutical composition is made up of the raw material of following weight parts:
Stigma Croci 2-8 part, Moschus 0.1-1.0 part, stir-baked SQUAMA MANITIS 1-5 part, Borneolum Syntheticum 0.1-0.5 part, Radix Notoginseng 2-10 part, generous eight 1-5 parts, Scolopendra 1-5 part, Radix Astragali 24-36 part, Radix Angelicae Sinensis 6-15 part, Rhizoma Chuanxiong 6-15 part, Pheretima 6-15 part, Radix Paeoniae Rubra 6-15 part, Semen Persicae 6-15 part, black-snake 6-15 part, Gekko Swinhonis 6-15 part, Radix Salviae Miltiorrhizae 6-15 part, Rhizoma Sparganii 6-15 part, Rhizoma Curcumae 6-15 part, Flos Carthami 6-15 part, Herba Lycopi 6-15 part, Lignum Sappan 6-15 part.
Be preferably:
Stigma Croci 4-6 part, Moschus 0.2-0.6 part, stir-baked SQUAMA MANITIS 2-4 part, Borneolum Syntheticum 0.2-0.4 part, Radix Notoginseng 4-8 part, generous eight 2-4 parts, Scolopendra 2-4 part, Radix Astragali 27-33 part, Radix Angelicae Sinensis 9-12 part, Rhizoma Chuanxiong 9-12 part, Pheretima 9-12 part, Radix Paeoniae Rubra 9-12 part, Semen Persicae 9-12 part, black-snake 9-12 part, Gekko Swinhonis 9-12 part, Radix Salviae Miltiorrhizae 9-12 part, Rhizoma Sparganii 9-12 part, Rhizoma Curcumae 9-12 part, Flos Carthami 9-12 part, Herba Lycopi 9-12 part, Lignum Sappan 9-12 part.
Optimum is:
5 parts of Stigma Crocis, 0.4 part, Moschus, 3 parts of stir-baked SQUAMA MANITISs, 0.3 part of Borneolum Syntheticum, 6 parts of Radix Notoginseng, generous 83 parts, 5 parts of Scolopendras, 30 parts of the Radixs Astragali, 10 parts of Radix Angelicae Sinensis, 10 parts of Rhizoma Chuanxiongs, 10 parts of Pheretimas, 10 parts of Radix Paeoniae Rubra, 10 parts, Semen Persicae, 10 parts of black-snakes, 10 parts of Gekko Swinhonis, 10 parts of Radix Salviae Miltiorrhizaes, 10 parts of Rhizoma Sparganii, 10 parts of Rhizoma Curcumae, 10 parts, Flos Carthami, 10 parts of Herba Lycopi, 10 parts of Lignum Sappans.
The pharmaceutical composition of above-mentioned treatment injury of oculomotor nerve paralysis can adopt existing conventional method to be prepared, preferably be prepared by the following method: take respectively above each raw material by proportional quantity, by Stigma Croci, Moschus, stir-baked SQUAMA MANITIS, Borneolum Syntheticum, Radix Notoginseng, generous eight and Scolopendra, clean and dry, co-grinding is crossed 60-80 mesh sieve, obtains powder or the encapsulated capsule that obtains; To remain above each raw material, and clean and dry, add making pellets by mixing medical powder with honey, obtain pill.
Preferably be prepared by the following method: take respectively above each raw material by proportional quantity, raw material except Moschus, Borneolum Syntheticum is decocted with water twice, add for the first time 7-8 times of water gaging, decoct 1.5-2 hour, add for the second time 6-8 times of water gaging, decoct 1-1.5 hour, collecting decoction, filter, then add Moschus, Borneolum Syntheticum, obtain decoction.
The dosage form of medicine of the present invention can be the medically acceptable dosage forms such as powder, capsule, decoction, pill, granule, tablet, and their preparation method, supplementary product consumption are undertaken by existing common process.
The present invention also comprises the application of aforementioned pharmaceutical compositions in the medicine of preparation treatment injury of oculomotor nerve paralysis.
In pharmaceutical composition prescription of the present invention:
Effect one: promoting blood circulation to remove obstruction in the collateral, dissipating blood stasis for subsidence of swelling.Take Stigma Croci, stir-baked SQUAMA MANITIS as principal agent, there is effect of dredging collateral promoting blood circulation and detumescence, be aided with pseudo-ginseng blood-circulation-invigovating, Scolopendra, generous eight dredging collateral, Moschus, Borneolum Syntheticum are sensible, have guide drugs to enter brain focus, are to eliminate paralysis/the recover side that wants of oculomotor nerve function.
Effect two: invigorating qi and dredging collateral, blood circulation promoting and blood stasis dispelling.With Radix Astragali QI invigorating, Radix Angelicae Sinensis is invigorated blood circulation, and the two is principal agent, auxiliary Rhizoma Chuanxiong, Radix Paeoniae Rubra, Semen Persicae, Radix Salviae Miltiorrhizae, Rhizoma Sparganii, Rhizoma Curcumae, Flos Carthami, Herba Lycopi, Lignum Sappan, assistant, with Scolopendra, black-snake, Pheretima, Gekko Swinhonis, has positive role for the own function of oculomotorius anti-inflammation detumescence recovery after cerebral lesion.
From the angle of the traditional Chinese medical science, injury of oculomotor nerve, etiology and pathology: after brain injuries, local organization is dampened, inflammation edema, and blood oozes out, make injury and produce blood vessel pressurized around, thrombosis, produces damage dysfunction as paralysis symptom after nerve damage, the traditional Chinese medical science thinks, due to wound, and qi depression to blood stasis, obstruction of meridians and collaterals, thus cause the serial symptom of " numbness ", in treatment should: promoting flow of QI and blood, dissipating blood stasis for subsidence of swelling, dredge the meridian passage.Therefore, pharmaceutical composition of the present invention, not only just for damage location, also for the meridians relevant with damage location, play comprehensive opsonic action, have promoting flow of QI and blood, dissipating blood stasis for subsidence of swelling, effect of promoting the flow of QI in the collateral by warming the meridian, strength is more powerful, in clinical use, and successful.
The specific embodiment
With embodiment, the invention will be further described below, but the present invention is not limited to these embodiment.
Embodiment 1:
Stigma Croci 20g, Moschus 10g, stir-baked SQUAMA MANITIS 10g, Borneolum Syntheticum 5g, Radix Notoginseng 20g, generous eight 50g, Scolopendra 10g, Radix Astragali 360g, Radix Angelicae Sinensis 60g, Rhizoma Chuanxiong 150g, Pheretima 60g, Radix Paeoniae Rubra 150g, Semen Persicae 60g, black-snake 60g, Gekko Swinhonis 150g, Radix Salviae Miltiorrhizae 60g, Rhizoma Sparganii 150g, Rhizoma Curcumae 60g, Flos Carthami 150g, Herba Lycopi 60g, Lignum Sappan 150g.
Take above each raw material, clean and dry, co-grinding is crossed 60 mesh sieves, obtains powder, incapsulates 0.5g/ grain.
Embodiment 2:
Stigma Croci 80g, Moschus 1g, stir-baked SQUAMA MANITIS 50g, Borneolum Syntheticum 1g, Radix Notoginseng 100g, generous eight 10g, Scolopendra 50g, Radix Astragali 240g, Radix Angelicae Sinensis 150g, Rhizoma Chuanxiong 60g, Pheretima 150g, Radix Paeoniae Rubra 60g, Semen Persicae 150g, black-snake 150g, Gekko Swinhonis 60g, Radix Salviae Miltiorrhizae 150g, Rhizoma Sparganii 60g, Rhizoma Curcumae 150g, Flos Carthami 60g, Herba Lycopi 150g, Lignum Sappan 60g.
Take above each raw material, clean and dry, co-grinding is crossed 60 mesh sieves, obtains powder, adds the magnesium stearate adjuvant of conventional amount used, and technique is made tablet routinely, specification 0.5g/ sheet
Embodiment 3:
Stigma Croci 40g, Moschus 6g, stir-baked SQUAMA MANITIS 20g, Borneolum Syntheticum 4g, Radix Notoginseng 40g, generous eight 40g, Scolopendra 20g, Radix Astragali 270g, Radix Angelicae Sinensis 120g, Rhizoma Chuanxiong 90g, Pheretima 120g, Radix Paeoniae Rubra 90g, Semen Persicae 120g, black-snake 120g, Gekko Swinhonis 90g, Radix Salviae Miltiorrhizae 120g, Rhizoma Sparganii 90g, Rhizoma Curcumae 120g, Flos Carthami 90g, Herba Lycopi 120g, Lignum Sappan 90g.
Take above each raw material, the raw material except Moschus, Borneolum Syntheticum is decocted with water to twice, add for the first time 7-8 times of water gaging, decoct 1.5-2 hour, add for the second time 6-8 times of water gaging, decoct 1-1.5 hour, collecting decoction, filters, then adds Moschus, Borneolum Syntheticum, obtains decoction.
Embodiment 4:
Stigma Croci 60g, Moschus 2g, stir-baked SQUAMA MANITIS 40g, Borneolum Syntheticum 2g, Radix Notoginseng 80g, generous eight 20g, Scolopendra 40g, Radix Astragali 330g, Radix Angelicae Sinensis 90g, Rhizoma Chuanxiong 120g, Pheretima 90g, Radix Paeoniae Rubra 120g, Semen Persicae 90g, black-snake 90g, Gekko Swinhonis 120g, Radix Salviae Miltiorrhizae 90g, Rhizoma Sparganii 120g, Rhizoma Curcumae 90g, Flos Carthami 120g, Herba Lycopi 90g, Lignum Sappan 120g.
Take above each raw material, clean and dry, co-grinding is crossed 80 mesh sieves, adds making pellets by mixing medical powder with honey, obtains pill.
Embodiment 5:
Stigma Croci 50g, Moschus 4g, stir-baked SQUAMA MANITIS 30g, Borneolum Syntheticum 3g, Radix Notoginseng 60g, generous eight 30g, Scolopendra 50g, Radix Astragali 300g, Radix Angelicae Sinensis 100g, Rhizoma Chuanxiong 100g, Pheretima 100g, Radix Paeoniae Rubra 100g, Semen Persicae 100g, black-snake 100g, Gekko Swinhonis 100g, Radix Salviae Miltiorrhizae 100g, Rhizoma Sparganii 100g, Rhizoma Curcumae 100g, Flos Carthami 100g, Herba Lycopi 100g, Lignum Sappan 100g.
Take above each raw material, by Stigma Croci, Moschus, stir-baked SQUAMA MANITIS, Borneolum Syntheticum, Radix Notoginseng, generous eight and Scolopendra, clean and dry, co-grinding is crossed 80 mesh sieves, obtains powder; To remain above each raw material, and clean and dry, add making pellets by mixing medical powder with honey, obtain pill.
In order to verify its effect, the product that embodiment 5 is obtained has carried out clinical verification in Guilin Third People's Hospital to 60 routine patients, and result is as follows:
Clinical data
1 data and method
1.1 clinical datas all enter 74 examples of group be during year October in January, 2008 to 2013 oculomotor paralysis patient to our hospital and treatment.60 routine patients are divided into 2 groups at random, each 30 examples for the treatment of group and matched group.Wherein treatment group man 16 examples, female's 14 examples; Patient age 22-61 year, year mean age (42.63 ± 5.58); Course of disease 2d to 5 month, average course of disease is (1.88 scholar 1.45) individual month.
1.2 diagnostic criterias are as follows with reference to diagnostic criteria formulation about one-sided " blepharoptosis " disease in " traditional Chinese medical science disease Standardization of diagnosis and curative effect ":
1) blepharoptosis, opens while looking squarely forward for two naturally, and upper eye lid hides black eyeball upper limb and exceedes 2mm, even hides pupil god; Affect vision; Press geisoma portion, upper eye lid is praised difficulty.
2) when patient looks thing, be and face upward head, raising the eyebrow up, the specific positions such as forehead wrinkle intensification.
3) one-sided blepharoptosis person, can be with other ballet's diseases, strabismus, and depending on one being two, mydriasis.
4) both sides blepharoptosis, heavy towards light dusk, spiritlessness and weakness, tired postemphasis.
5) get rid of serious hepatic and kidney function obstacle patient, and this institute is used to the patient of drug allergy.
1.3 Therapeutic Method
30 routine patients of matched group give methycobal [defend material (China) pharmaceutcal corporation, Ltd authentication code: the accurate word H20030812 of traditional Chinese medicines, 0.5mg/ sheet], 1 time 1,3 times on the 1st.The routine patient for the treatment of group 30 takes the finished product that embodiment 5 obtains.
Oral comparative example of the present invention 5:
Usage: powder, every day 2-3 time, each 3 to 5 grams, warm water takes.
Honeyed pill, every day 3 times, each 1 ball.
2, criterion of therapeutical effect
Recovery from illness: blepharoptosis recovers, the motion of eyeball all directions is not limited, and eyeball all recovers normally, without diplopia and platycoria.
Effective: blepharoptosis recovers, eyeball a certain orientation motion is slightly limited, and diplopia image distance is from obviously dwindling, and platycoria obviously dwindles.
Invalid: treatment front and back are without change or only have MC.
3, therapeutic outcome
Table 1 liang group patient treatment curative effect comparison
Conclusion: generally take medicine and start appearance effect for one month, effective or recovery completely in 3 to 5 months.Through being no more than to the 30 example treatment patients statistics of 90 days the injured time after 2008, effective 30 examples, effective percentage reaches 100%, and symptom disappears completely, normal person's 28 examples of functional rehabilitation, cure rate is 93.33%.
Claims (6)
1. treat a pharmaceutical composition for injury of oculomotor nerve paralysis, it is characterized in that it is made up of the raw material of following weight parts respectively:
Stigma Croci 2-8 part, Moschus 0.1-1.0 part, stir-baked SQUAMA MANITIS 1-5 part, Borneolum Syntheticum 0.1-0.5 part, Radix Notoginseng 2-10 part, generous eight 1-5 parts, Scolopendra 1-5 part, Radix Astragali 24-36 part, Radix Angelicae Sinensis 6-15 part, Rhizoma Chuanxiong 6-15 part, Pheretima 6-15 part, Radix Paeoniae Rubra 6-15 part, Semen Persicae 6-15 part, black-snake 6-15 part, Gekko Swinhonis 6-15 part, Radix Salviae Miltiorrhizae 6-15 part, Rhizoma Sparganii 6-15 part, Rhizoma Curcumae 6-15 part, Flos Carthami 6-15 part, Herba Lycopi 6-15 part, Lignum Sappan 6-15 part.
2. a kind of pharmaceutical composition for the treatment of injury of oculomotor nerve paralysis according to claim 1, is characterized in that: the weight portion of each raw material is:
Stigma Croci 4-6 part, Moschus 0.2-0.6 part, stir-baked SQUAMA MANITIS 2-4 part, Borneolum Syntheticum 0.2-0.4 part, Radix Notoginseng 4-8 part, generous eight 2-4 parts, Scolopendra 2-4 part, Radix Astragali 27-33 part, Radix Angelicae Sinensis 9-12 part, Rhizoma Chuanxiong 9-12 part, Pheretima 9-12 part, Radix Paeoniae Rubra 9-12 part, Semen Persicae 9-12 part, black-snake 9-12 part, Gekko Swinhonis 9-12 part, Radix Salviae Miltiorrhizae 9-12 part, Rhizoma Sparganii 9-12 part, Rhizoma Curcumae 9-12 part, Flos Carthami 9-12 part, Herba Lycopi 9-12 part, Lignum Sappan 9-12 part.
3. a kind of pharmaceutical composition for the treatment of injury of oculomotor nerve paralysis according to claim 2, is characterized in that: the weight portion of each raw material is:
5 parts of Stigma Crocis, 0.4 part, Moschus, 3 parts of stir-baked SQUAMA MANITISs, 0.3 part of Borneolum Syntheticum, 6 parts of Radix Notoginseng, generous 83 parts, 5 parts of Scolopendras, 30 parts of the Radixs Astragali, 10 parts of Radix Angelicae Sinensis, 10 parts of Rhizoma Chuanxiongs, 10 parts of Pheretimas, 10 parts of Radix Paeoniae Rubra, 10 parts, Semen Persicae, 10 parts of black-snakes, 10 parts of Gekko Swinhonis, 10 parts of Radix Salviae Miltiorrhizaes, 10 parts of Rhizoma Sparganii, 10 parts of Rhizoma Curcumae, 10 parts, Flos Carthami, 10 parts of Herba Lycopi, 10 parts of Lignum Sappans.
4. according to the preparation method of the pharmaceutical composition described in any one in claim 1-3, it is characterized in that: take respectively each raw material by proportional quantity, by Stigma Croci, Moschus, stir-baked SQUAMA MANITIS, Borneolum Syntheticum, Radix Notoginseng, generous eight and Scolopendra, clean and dry, co-grinding is crossed 60-80 mesh sieve, obtains powder or the encapsulated capsule that obtains, to remain each raw material, clean and dry, add making pellets by mixing medical powder with honey, obtain pill.
5. according to the preparation method of the pharmaceutical composition described in any one in claim 1-3, it is characterized in that: take respectively each raw material by proportional quantity, raw material except Moschus, Borneolum Syntheticum is decocted with water to twice, add for the first time 7-8 times of water gaging, decoct 1.5-2 hour, add for the second time 6-8 times of water gaging, decoct 1-1.5 hour, collecting decoction, filters, add again Moschus, Borneolum Syntheticum, obtain decoction.
6. the application of the pharmaceutical composition described in any one in the medicine of preparation treatment injury of oculomotor nerve paralysis in claim 1-3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310632018.9A CN103816476B (en) | 2013-12-02 | 2013-12-02 | A kind of pharmaceutical composition treating injury of oculomotor nerve paralysis and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310632018.9A CN103816476B (en) | 2013-12-02 | 2013-12-02 | A kind of pharmaceutical composition treating injury of oculomotor nerve paralysis and its preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103816476A true CN103816476A (en) | 2014-05-28 |
| CN103816476B CN103816476B (en) | 2016-08-24 |
Family
ID=50751956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310632018.9A Expired - Fee Related CN103816476B (en) | 2013-12-02 | 2013-12-02 | A kind of pharmaceutical composition treating injury of oculomotor nerve paralysis and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103816476B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104922285A (en) * | 2015-06-28 | 2015-09-23 | 李先强 | Combined traditional Chinese medicine for treating Miller Fisher syndrome |
| CN105168631A (en) * | 2015-10-23 | 2015-12-23 | 徐素萍 | Nursing traditional Chinese medicine for relieving post-anesthesia nerve injuries |
| CN105434645A (en) * | 2015-12-29 | 2016-03-30 | 青岛昌安达药业有限公司 | Traditional Chinese medicine composition used for treating facial nerve paralysis |
| CN105434646A (en) * | 2015-12-29 | 2016-03-30 | 青岛昌安达药业有限公司 | Traditional Chinese medicine decoction used for treating facial nerve paralysis |
| CN105434647A (en) * | 2015-12-29 | 2016-03-30 | 青岛昌安达药业有限公司 | Traditional Chinese medicine preparation for treating facioplegia |
-
2013
- 2013-12-02 CN CN201310632018.9A patent/CN103816476B/en not_active Expired - Fee Related
Non-Patent Citations (1)
| Title |
|---|
| 毛照海: "中药内服外用治疗后天性动眼神经麻痹11例", 《中国中医药信息杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104922285A (en) * | 2015-06-28 | 2015-09-23 | 李先强 | Combined traditional Chinese medicine for treating Miller Fisher syndrome |
| CN105168631A (en) * | 2015-10-23 | 2015-12-23 | 徐素萍 | Nursing traditional Chinese medicine for relieving post-anesthesia nerve injuries |
| CN105434645A (en) * | 2015-12-29 | 2016-03-30 | 青岛昌安达药业有限公司 | Traditional Chinese medicine composition used for treating facial nerve paralysis |
| CN105434646A (en) * | 2015-12-29 | 2016-03-30 | 青岛昌安达药业有限公司 | Traditional Chinese medicine decoction used for treating facial nerve paralysis |
| CN105434647A (en) * | 2015-12-29 | 2016-03-30 | 青岛昌安达药业有限公司 | Traditional Chinese medicine preparation for treating facioplegia |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103816476B (en) | 2016-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100506274C (en) | Traditional Chinese medicine for treating cervical vertebra disease | |
| CN102228603B (en) | Chinese medicine for treating retention of urine | |
| CN102935153A (en) | Qi reinforcing qianzheng pills for cerebral thrombosis disease treatment | |
| CN103816476A (en) | Medicine composition for treating injury and paralysis of oculomotor nerve and preparation method and application thereof | |
| CN103006951A (en) | Chinese medicinal composition for treating cervical spondylosis and lumbar spondylosis | |
| CN104398982A (en) | Traditional Chinese medicine composition for treating traumatic injury and joint pain and swelling | |
| CN1390585A (en) | Chinese medicine for detoxication purpose and its preparing process | |
| CN102441145A (en) | Medicament for treating lumbar disc herniation and cervical spondylosis | |
| CN103301326A (en) | Medicament for treating rheumatism, rheumatoid and pain or rheumatism in lower extremities and waist | |
| CN101007159B (en) | Traditional Chinese medicine for preventing and controlling tumor | |
| CN102512645B (en) | Traditional Chinese medicine composition for treating lumbago due to cold dampness | |
| CN104547633A (en) | Traditional Chinese medicine composition for treating cervical vertebra disease and preparation method thereof | |
| CN103638234A (en) | Traditional Chinese medicine composition for treating tinnitus, preparation and preparation method thereof | |
| CN102784234A (en) | Traditional Chinese medicine composition for treating chronic urticaria | |
| CN103638510B (en) | A kind of Chinese medicinal formulae for the treatment of neck-shoulder pain, lumbago and leg pain and preparation method thereof | |
| CN109999098A (en) | It is a kind of for treating the traditional Chinese medicine for external application of cancer-related sleep disturbance | |
| CN116942740B (en) | Traditional Chinese medicine composition for treating lumbar disc herniation and application thereof | |
| CN110841007B (en) | Traditional Chinese medicine composition for treating cerebral apoplexy sequela and application thereof | |
| CN103393757B (en) | Traditional Chinese medicine decoction for treating radioactive brain damage | |
| CN102178758A (en) | Medicament for treating peripheral nerve of diabetes | |
| CN102512562B (en) | Pharmaceutical composition for treating ischemic cerebrovascular diseases and preparation method and applications thereof | |
| CN115804805B (en) | Traditional Chinese medicine compound composition for treating ankylosing spondylitis and external medicine bag | |
| CN101279069A (en) | Medicament composite for dredging channels and collaterals, and promoting blood-circulation and removing blood stasis, and method of preparing the same | |
| CN105194411A (en) | Formula of traditional Chinese medicine for treating scapulobumeral periarthritis | |
| CN105770279A (en) | Anti-osteoporosis rejuvenation paste |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160824 Termination date: 20181202 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |